Penumbra, Inc. (PEN)

Market Cap	12.86B +22.2%
Revenue (ttm)	1.40B +17.5%
Net Income	177.69M +1,168.1%
EPS	4.52 +1,155.6%
Shares Out	39.32M
PE Ratio	72.35
Forward PE	65.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,085,298
Open	329.75
Previous Close	329.71
Day's Range	327.00 - 330.07
52-Week Range	221.26 - 362.41
Beta	0.84
Analysts	Buy
Price Target	357.33 (+9.28%)
Earnings Date	Apr 30, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,700
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Analyst Summary

According to 17 analysts, the average rating for PEN stock is "Buy." The 12-month stock price target is $357.33, which is an increase of 9.28% from the latest price.

Price Target

$357.33

(9.28% upside)

Analyst Consensus: Buy